MX337612B - Composicion de oligosacaridos para prevenir o reducir el riesgo de sindrome metabolico. - Google Patents

Composicion de oligosacaridos para prevenir o reducir el riesgo de sindrome metabolico.

Info

Publication number
MX337612B
MX337612B MX2013015036A MX2013015036A MX337612B MX 337612 B MX337612 B MX 337612B MX 2013015036 A MX2013015036 A MX 2013015036A MX 2013015036 A MX2013015036 A MX 2013015036A MX 337612 B MX337612 B MX 337612B
Authority
MX
Mexico
Prior art keywords
risk
preventing
reducing
metabolic syndrome
oligosaccharides composition
Prior art date
Application number
MX2013015036A
Other languages
English (en)
Other versions
MX2013015036A (es
Inventor
Georgios Tzortzis
Jelena Vulevic
Original Assignee
Clasado Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clasado Inc filed Critical Clasado Inc
Publication of MX2013015036A publication Critical patent/MX2013015036A/es
Publication of MX337612B publication Critical patent/MX337612B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona al uso de una composición de galactooligosacárido para prevenir o reducir el riesgo de desarrollar síndrome metabólico.
MX2013015036A 2011-07-05 2012-06-20 Composicion de oligosacaridos para prevenir o reducir el riesgo de sindrome metabolico. MX337612B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1111452.7A GB2492559B (en) 2011-07-05 2011-07-05 Composition and method for preventing or reducing the risk of developing a syndrome
PCT/GB2012/051418 WO2013005001A1 (en) 2011-07-05 2012-06-20 Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome

Publications (2)

Publication Number Publication Date
MX2013015036A MX2013015036A (es) 2014-02-17
MX337612B true MX337612B (es) 2016-03-10

Family

ID=44512110

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015036A MX337612B (es) 2011-07-05 2012-06-20 Composicion de oligosacaridos para prevenir o reducir el riesgo de sindrome metabolico.

Country Status (24)

Country Link
US (2) US11052097B2 (es)
EP (1) EP2729152B1 (es)
JP (1) JP2014518253A (es)
KR (1) KR20140041597A (es)
CN (2) CN107744522A (es)
AR (1) AR087062A1 (es)
AU (1) AU2012203730B2 (es)
BR (1) BR112013030308A2 (es)
CA (1) CA2838309C (es)
CY (1) CY1117170T1 (es)
DK (1) DK2729152T3 (es)
ES (1) ES2562993T3 (es)
GB (1) GB2492559B (es)
HU (1) HUE027148T2 (es)
IL (1) IL230251A (es)
MX (1) MX337612B (es)
MY (1) MY173722A (es)
PL (1) PL2729152T3 (es)
PT (1) PT2729152E (es)
RU (1) RU2571079C2 (es)
TW (1) TWI461200B (es)
UA (1) UA111616C2 (es)
WO (1) WO2013005001A1 (es)
ZA (1) ZA201308776B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2492559B (en) * 2011-07-05 2018-07-25 Clasado Inc Composition and method for preventing or reducing the risk of developing a syndrome
GB201319538D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
KR102029263B1 (ko) * 2018-05-16 2019-11-08 주식회사 비피도 베타-엘-푸코피라노실-(1→3)-옥시-디-갈락토피라노오스를 포함하는 프리바이오틱스 조성물
GB2623336A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62210965A (ja) 1986-03-13 1987-09-17 Shokuhin Sangyo Baioriakutaa Syst Gijutsu Kenkyu Kumiai 低カロリ−飲食品およびその製造方法
JP2699470B2 (ja) 1988-10-19 1998-01-19 大日本インキ化学工業株式会社 食品保存剤及びその製造方法
US6368591B2 (en) * 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
ITMI20002019A1 (it) * 1999-09-17 2002-03-15 Novartis Ag Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete
JP2003339348A (ja) * 2002-05-27 2003-12-02 Toyo Shinyaku:Kk 健康食品
ATE360682T1 (de) * 2003-06-30 2007-05-15 Clasado Inc Neue galactooligosaccharidzusammensetzung und herstellung davon
GB0315266D0 (en) * 2003-06-30 2003-08-06 Clasado Inc Novel galactooligosaccharide composition and the preparation thereof
DE102005034262A1 (de) * 2005-07-22 2007-01-25 Bayer Healthcare Ag Substituierte Pyridocarboxamide II
WO2008054193A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Nutritional products that comprise saccharide oligomers
EP2143341A1 (en) 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
GB0809921D0 (en) * 2008-05-30 2008-07-09 Clasado Inc Product and process therefor
JP5238373B2 (ja) * 2008-06-25 2013-07-17 株式会社ヤクルト本社 腸間膜脂肪低減剤
GB0906983D0 (en) * 2009-04-23 2009-06-03 Clasado Inc Novel use
US11065268B2 (en) * 2009-05-27 2021-07-20 Clasado Research Services Limited Method of preventing diarrhoea
US8951512B2 (en) * 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
GB2492559B (en) * 2011-07-05 2018-07-25 Clasado Inc Composition and method for preventing or reducing the risk of developing a syndrome
GB201305708D0 (en) * 2013-03-28 2013-05-15 Clasado Inc Novel use

Also Published As

Publication number Publication date
CN103648504A (zh) 2014-03-19
EP2729152B1 (en) 2015-12-30
US20210330688A1 (en) 2021-10-28
ES2562993T3 (es) 2016-03-09
JP2014518253A (ja) 2014-07-28
AU2012203730B2 (en) 2013-10-31
KR20140041597A (ko) 2014-04-04
CA2838309A1 (en) 2013-01-10
AU2012203730A1 (en) 2013-01-24
MX2013015036A (es) 2014-02-17
CN107744522A (zh) 2018-03-02
IL230251A (en) 2017-03-30
CY1117170T1 (el) 2017-04-05
WO2013005001A1 (en) 2013-01-10
MY173722A (en) 2020-02-18
US20140142061A1 (en) 2014-05-22
RU2014103800A (ru) 2015-08-10
GB2492559B (en) 2018-07-25
AR087062A1 (es) 2014-02-12
CA2838309C (en) 2017-04-18
US11052097B2 (en) 2021-07-06
RU2571079C2 (ru) 2015-12-20
ZA201308776B (en) 2015-04-29
PL2729152T3 (pl) 2016-06-30
GB201111452D0 (en) 2011-08-17
BR112013030308A2 (pt) 2016-11-29
TW201313235A (zh) 2013-04-01
DK2729152T3 (en) 2016-01-25
TWI461200B (zh) 2014-11-21
PT2729152E (pt) 2016-03-04
GB2492559A (en) 2013-01-09
EP2729152A1 (en) 2014-05-14
NZ617764A (en) 2015-08-28
HUE027148T2 (en) 2016-10-28
UA111616C2 (uk) 2016-05-25

Similar Documents

Publication Publication Date Title
JOP20180102B1 (ar) مركب صيدلاني
EP2681268B8 (en) Organosiloxane compositions
MX2013002264A (es) Composiciones pesticidas.
EP2661179A4 (en) COMPOSITION WITH REDUCED SODIUM CONTENT
IL228630A0 (en) Compounds for the treatment of the metabolic syndrome
BR112014014896A2 (pt) nova combinação
IL232194A (en) An iontophoresis cross-linking preparation for use in keratoconus treatment
GB201101331D0 (en) Compositions and uses
EP2682116A4 (en) AGENT IMPROVING METABOLIC SYNDROME
PT2723336T (pt) Composições para o tratamento da síndrome do x frágil
MX337612B (es) Composicion de oligosacaridos para prevenir o reducir el riesgo de sindrome metabolico.
MX347541B (es) Analogos de acido sialico.
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
EP2683746A4 (en) OLIGOSACCHARIDE COMPOUNDS
LV14606A (lv) Jauns XII faktora inhibitors
PT2686006T (pt) Resumo
MY151659A (en) Photopolymerizable Resin Composition
MX2012012509A (es) Tapentadol para usarse en el tratamiento del sindrome del intestino irritable.
UA106373C2 (ru) Применение поллентара как средства фригопротекторного действия
HUP1100268A2 (en) Nasale composition for the prevention of venous trombosis
UA94339C2 (ru) применение корвитина в качестве средства фригопротекторного действия
UA96060C2 (ru) Применение липофлавона как средства фригопротекторного действия
EP2815756A4 (en) COMPOSITION FOR THE PREVENTION, TREATMENT OR TREATMENT OF METABOLIC SYNDROME
UA72478U (ru) Применение полентара как средства фригопротекторного действия

Legal Events

Date Code Title Description
FG Grant or registration